Literature DB >> 22900600

Fluoxetine attenuates chronic methamphetamine-induced pulmonary arterial remodelling: possible involvement of serotonin transporter and serotonin 1B receptor.

Ming Liu1, Yun Wang, Han-ming Wang, Yang Bai, Xin-hua Zhang, Ying-xian Sun, Huai-liang Wang.   

Abstract

Epidemiological data have shown that methamphetamine (MA) abuse significantly increases the risk of developing pulmonary arterial hypertension (PAH). To investigate whether MA could induce PAH and its possible mechanism, rats were exposed daily to MA for 5 weeks in the absence or presence of fluoxetine. The results showed that the pulmonary arterial pressure was not significantly increased, but the pulmonary arterial remodelling was markedly developed in the MA exposure group. The protein expressions of the serotonin transporter (5-HTT) and 5-HT(1B) receptor were increased in the lungs and in the pulmonary arteries of MA-treated rats. Fluoxetine attenuated the pulmonary arterial remodelling and down-regulated the protein expression of 5-HTT and 5-HT(1B) receptor in pulmonary arteries of MA-treated rats. These findings suggest that fluoxetine has a novel potential suppressive effect on the chronic MA-induced pulmonary vascular remodelling and also suggest that 5-HTT and 5-HT(1B) receptor may be involved as part of its mechanism.
© 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22900600     DOI: 10.1111/j.1742-7843.2012.00933.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  8 in total

Review 1.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

2.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

3.  Stimulants and Pulmonary Arterial Hypertension: An Update.

Authors:  Ramon L Ramirez; Vinicio De Jesus Perez; Roham T Zamanian
Journal:  Adv Pulm Hypertens       Date:  2018

Review 4.  Methamphetamine and the risk of pulmonary arterial hypertension.

Authors:  Ramon L Ramirez; Vinicio De Jesus Perez; Roham T Zamanian
Journal:  Curr Opin Pulm Med       Date:  2018-09       Impact factor: 3.155

Review 5.  Stimulants and the lung : review of literature.

Authors:  Will Tseng; Mark E Sutter; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

6.  Fluoxetine protects against methamphetamine‑induced lung inflammation by suppressing oxidative stress through the SERT/p38 MAPK/Nrf2 pathway in rats.

Authors:  Yun Wang; Yu-Han Gu; Ming Liu; Yang Bai; Huai-Liang Wang
Journal:  Mol Med Rep       Date:  2016-12-23       Impact factor: 2.952

7.  Sex-dependent right ventricular hypertrophic gene changes after methamphetamine treatment in mice.

Authors:  Hicham Labazi; Margaret Nilsen; Margaret R MacLean
Journal:  Eur J Pharmacol       Date:  2021-03-28       Impact factor: 4.432

Review 8.  Gender, sex hormones and pulmonary hypertension.

Authors:  Eric D Austin; Tim Lahm; James West; Stevan P Tofovic; Anne Katrine Johansen; Margaret R Maclean; Abdallah Alzoubi; Masahiko Oka
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.